VertiGraft Clinical Review

Clinical Reports using VertiGraft in Cervical ACDF

Abla A, El Kadi H, Bost J, Maroon J, and Wert M. Allograft Composite Cortical and Cancellous Bone Graft for Anterior Cerival Fusion.Contemporary Neurosurgery: A Biweekly Publication for Clinical Neurosurgical Continuing Medical Education. 2005;27(8):1-6.

The authors used the LifeNet Health (LNH) VG2 cervical bio-implant in ACDF surgery for patients with cervical spine stenosis orspondylosis. This prospective study evaluated the ACDF surgery results of 74 patients. The authors reported favorable outcomeresults with no graft failures and 90% patient satisfaction at 12 months follow-up.

Fox B, Gopez A, Sukovich W, and Kerner M. Anterior Cervical Spine Fusion Rates Using a Frozen Laminated Composite Allograft and Plating.The Internet Journal of Spine Surgery. 2005; 2(1).

The authors used VG2 cervical allografts in ACDF surgery for patients with cervical disc herniation and cervical Spondylosis.This was a retrospective, cohort study with 92 enrolled patients and a 2 year follow-up. The results suggested that 138 of 146(94.5%) of attempted levels showed solid fusion. The VG2 graft was considered successful with the authors noting that the VG2“demonstrates fusion rates similar or better than those reported for [iliac autografts and other types of allografts].”

Rodway I, and Gander J. Comparison of Fusion Rates between Glycerol-Preserved and Frozen Composite Allografts in Cervical Fusion.International Scholarly Research Notices. 2014; 2014:960142.

Investigators compared fusion rates after anterior cervical discectomy and fusion using frozen state and glycerol-preserved VG2cervical allografts. This retrospective, two cohort series study consisted of 67 patients with a minimum 1 year follow-up. Onehundred percent fusion rate was determined for both treatment groups at 12 months, and each had similar rates at short-termfollow-ups. Authors noted “While not generalizable, these results are encouraging and support the use of [Preservon] allograftsfror ACDF surgery.”

McAnany SJ, Ahn J, Elboghdady IM, Marquez-Lara A, Ashraf N, Svovrlj B, Overly SC, Singh K, Qureshi SA. Mesenchymal Stem Cell Allograft as a Fusion Adjunct in One- and Two-level Anterior Cervical Discectomy and Fusion: A Matched Cohort Analysis. The Spine Journal. 2016; (16): 163-167.

This matched cohort study compared the fusion rates between the use of mesenchymal cell allografts and non-mesenchymal allografts (Vertigraft) in 57 patients who underwent ACDF. Results showed that 50 of 57 (87.7%) of MSC cohort versus 54 of 57 (94.7%) of non-MSC cohort showed solid fusion at 1-year follow-up. The authors also reported that 7 (12.3%) patients with MSC grafts were considered failed fusions at 1 year. The authors concluded that although rates between the two cohorts were not statistically significant, patients treated with MSC allografts showed lower fusion rates compared with matched non-MSC allografts.

Miller LE & Block JE. “Safety and Effectiveness of Bone Allografts in Anterior Cervical Discectomy and Fusion Surgery.” 2011 White Paper (68-20-014)

This systematic review compared clinical and radiographic outcomes of ACDF using allograft, autograft, cages with and without bone graft substitute, and cervical arthroplasty for the treatment of cervical disc disease. The authors concluded that bone allograft is a safe and effective option in ACDF treatment and offers advantages such as high fusion rates, no donor site morbidity, and low incidence of adverse events.